These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16247595)

  • 1. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
    Dowsett M; Nicholson RI; Pietras RJ
    Breast Cancer Res Treat; 2005; 93 Suppl 1():S11-8. PubMed ID: 16247595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Life following aromatase inhibitors--where now for endocrine sequencing?
    Johnston SR; Martin LA; Dowsett M
    Breast Cancer Res Treat; 2005; 93 Suppl 1():S19-25. PubMed ID: 16247596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine therapy--current benefits and limitations.
    Nicholson RI; Johnston SR
    Breast Cancer Res Treat; 2005; 93 Suppl 1():S3-10. PubMed ID: 16247594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
    Johnston SR; Martin LA; Head J; Smith I; Dowsett M
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):173-81. PubMed ID: 15996863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
    Vergote I; Robertson JF; Kleeberg U; Burton G; Osborne CK; Mauriac L; ;
    Breast Cancer Res Treat; 2003 May; 79(2):207-11. PubMed ID: 12825855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant ('Faslodex'): extending the reach of endocrine therapy?
    Johnston SR
    Breast Cancer Res Treat; 2005; 93 Suppl 1():S1-2. PubMed ID: 16247593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new estrogen receptor antagonist--an overview of available data.
    Jones SE
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S19-21; discussion S33-5. PubMed ID: 12353819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant and the sequential endocrine cascade for advanced breast cancer.
    Johnston S
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S15-8. PubMed ID: 15094760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Bundred N
    Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
    Scott SM; Brown M; Come SE
    Expert Opin Drug Saf; 2011 Sep; 10(5):819-26. PubMed ID: 21699443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.
    Buzdar AU
    Drugs Today (Barc); 2004 Sep; 40(9):751-64. PubMed ID: 15538548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
    Morris C; Wakeling A
    Endocr Relat Cancer; 2002 Dec; 9(4):267-76. PubMed ID: 12542403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
    Chia S; Gradishar W
    Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.
    Vergote I; Amant F; Leunen K; Van Gorp T; Berteloot P; Neven P
    Int J Gynecol Cancer; 2006; 16 Suppl 2():524-6. PubMed ID: 17010064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
    Oakman C; Moretti E; Santarpia L; Di Leo A
    Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
    Osborne CK; Wakeling A; Nicholson RI
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S2-6. PubMed ID: 15094757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.